STOCK TITAN

Biocept Inc - BIOC STOCK NEWS

Welcome to our dedicated news page for Biocept (Ticker: BIOC), a resource for investors and traders seeking the latest updates and insights on Biocept.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biocept's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biocept's position in the market.

Rhea-AI Summary
Biocept announces full enrollment of subjects in feasibility phase of FORESEE clinical trial for CNSide assay
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
-
Rhea-AI Summary
Biocept signs non-exclusive licensing agreement for CNSide with Plus Therapeutics for clinical trial on targeted radiotherapeutic. Plus will pay Biocept $150,000 upfront fee in stock and $6,000 per CSF tumor cell enumeration analysis. Positive validation of CNSide's clinical utility and potential future agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
59.52%
Tags
none
-
Rhea-AI Summary
Biocept to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.89%
Tags
conferences
Rhea-AI Summary
Biocept, Inc. will hold a conference call on August 30, 2023, to provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
Rhea-AI Summary
Biocept, Inc. (Nasdaq: BIOC) reports financial results for the second quarter of 2023, with net revenues at $0.6 million and a net loss of $3.6 million. The company is focused on establishing its proprietary cerebrospinal fluid assay CNSide™ as standard of care and is making progress in the FORESEE clinical trial. Biocept also plans to provide further evidence of CNSide’s clinical utility through publication in peer-reviewed medical journals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
-
Rhea-AI Summary
Biocept's CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 SNO/ASCO CNS Cancer Conference. The assay showed promise in detecting leptomeningeal metastasis (LM) and improving treatment decisions. HER2 amplification in the CSF was found in a significant number of patients with LM, suggesting potential targeted therapies. Circulating tumor cell (CTC) analysis using CNSide provided superior sensitivity in detecting leptomeningeal carcinomatosis (LMC) compared to traditional cytology, allowing for earlier detection and treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
Rhea-AI Summary
Biocept, Inc. announces the passing of M. Faye Wilson, Board Chair. Wilson was a respected business executive and philanthropist known for her advocacy for women's rights and equality in the workplace. The company expresses condolences and appoints new Board Chair and Vice Chair.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.27%
Tags
none
-
Rhea-AI Summary
Biocept to present at Maxim Group Virtual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
Biocept Inc

Nasdaq:BIOC

BIOC Rankings

BIOC Stock Data

1.14M
2.62M
9.21%
1.98%
0.57%
Medical Laboratories
Health Care and Social Assistance
Link
US
San Diego

About BIOC

biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar